secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-207537
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q1 net loss $84.8M ($0.99/share); DURAVYU Phase 3 wet AMD data expected mid-2026
--------------------------------------------------------------------------------

- Q1 2026 revenue $0.7M vs $24.5M YoY, driven by YUTIQ license deferral; operating expenses $87.9M.
- Cash & investments $223M at March 31, 2026, runway into Q4 2027; down from $306M at year-end 2025.
- Phase 3 wet AMD trials (LUGANO/LUCIA) topline data due mid-2026; over 900 patients enrolled.
- Phase 3 DME trials (COMO/CAPRI) >1/3 enrolled; full enrollment expected Q3 2026, topline Q4 2027.
- New ARVO 2026 data show vorolanib inhibits JAK1/IL-6, supporting multi-mechanism anti-inflammatory effect.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526207537/0001193125-26-207537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526207537/eypt-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-207537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer